Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ElectroCore Inc (ECOR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$8.80+4.76%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ECOR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce losses and improve earnings trajectory | A supporting condition in ElectroCore Inc's published investment case. The stated target is EPS loss narrows from -$1.5 in 2026 to less negative in 2027. | Improving | EPS loss worsens or remains flat beyond 2027 | Diluted EPS: $-0.13 per share FY2026-Q3; GAAP. Published target: EPS loss narrows from -$1.5 in 2026 to less negative in 2027. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 2026-0.13 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not yet a profitable compounder. The long-term thesis is on watch: revenue growth and VA-channel expansion are progressing, but recent financial performance trails its industry cohort and losses remain.
The evidence snapshot gives no valuation multiple or direct measure of market expectations, so valuation cannot be described reliably. The clearest expectation is management’s raised 2026 revenue guidance for growth above 30%, alongside a goal of positive adjusted EBITDA by Q3 2027.
Near term, revenue growth and VA prescriptions support the business, and adjusted EBITDA losses have narrowed, but the company is still loss-making. The main execution test is whether growth continues and losses keep shrinking; a guidance reversal would also damage management credibility.
The multi-year view hinges on delivering the raised revenue outlook and reaching positive adjusted EBITDA on the stated timeline. Weakening jobs data could pressure cyclical healthcare names, while continued strong results from sector bellwethers could support the sector backdrop.
Over the next 1 to 3 years, ECOR’s thesis remains an execution story: growth is advancing, but profitability is unproven and risk is elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Improve gross profit margins through operational efficiencies | Gross profit improved from $7.5M in 2025-Q3 to $8.4M in 2026-Q1. | Under Pressure | gross profit margin declines below 2025-Q3 levels persistently | Gross margin: 88.47% FY2026-Q3; GAAP. Published target: gross profit margin improves or remains stable relative to 2026-Q1 levels. Target percentage unit is not explicit. Nov 4, 202688.472652 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve approximately 30% annual revenue growth in 2026 | A primary condition in ElectroCore Inc's published investment case. The stated target is >=30% annual growth in 2026. | Improving | annual revenue growth falls below 15% in 2026 | Revenue growth: 11.52% FY2026-Q3; GAAP. Published target: >=30% annual growth in 2026. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 202611.520313 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.42 → $-0.62 · observed estimates
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.42 | $53,902,900 | 3 / 4 |
| 2026-07-25 | $-0.42 | $53,902,900 | 3 / 4 |
| 2026-07-26 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-07-27 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-07-28 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-07-29 | $-0.42 | $53,902,900 | 3 / 4 |
| 2026-07-30 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-07-31 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-08-01 | $-0.42 | $53,902,900 | 3 / 4 |
| 2026-08-02 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-08-03 | $-0.42 | $53,902,900 | 3 / 4 |
| 2026-08-04 | $-0.42 | $53,902,900 | 3 / 4 |
| 2026-08-05 | $-0.42 | $53,902,900 | 3 / 4 |
| 2026-08-06 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-08-07 | $-0.43 | $53,902,900 | 3 / 4 |
| 2026-08-08 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-08-09 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-08-10 | $-0.43 | $54,228,200 | 4 / 5 |
| 2026-08-11 | $-0.43 | $53,902,900 | 3 / 4 |
| 2026-08-12 | $-0.44 | $54,366,800 | 3 / 5 |
| 2026-08-13 | $-0.44 | $54,366,800 | 3 / 5 |
| 2026-08-14 | $-0.43 | $53,902,900 | 3 / 4 |
| 2026-08-15 | $-0.43 | $53,902,900 | 3 / 4 |
| 2026-08-16 | $-0.43 | $53,902,900 | 3 / 4 |
| 2026-08-17 | $-0.43 | $53,902,900 | 3 / 4 |
| 2026-08-18 | $-0.43 | $53,902,900 | 3 / 4 |
| 2026-08-19 | $-0.43 | $53,902,900 | 3 / 4 |
| 2026-08-20 | $-0.46 | $53,436,750 | 3 / 4 |
| 2026-08-21 | $-0.46 | $53,436,750 | 3 / 4 |
| 2026-08-22 | $-0.46 | $53,436,750 | 3 / 4 |
| 2026-08-23 | $-0.46 | $53,436,750 | 3 / 4 |
| 2026-08-24 | $-0.46 | $53,436,750 | 3 / 4 |
| 2026-08-25 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-08-26 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-08-27 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-08-28 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-08-29 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-08-30 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-08-31 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-01 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-02 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-03 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-04 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-05 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-06 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-07 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-08 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-09 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-10 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-11 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-12 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-13 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-14 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-15 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-16 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-17 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-18 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-19 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-20 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-21 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-22 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-23 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-24 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-25 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-26 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-27 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-28 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-29 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-09-30 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-01 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-02 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-03 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-04 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-05 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-06 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-07 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-08 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-09 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-10 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-11 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-12 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-13 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-14 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-15 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-16 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-17 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-18 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-19 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-20 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-21 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-22 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-23 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-24 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-25 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-26 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-27 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-28 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-29 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-30 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-10-31 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-11-01 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-11-02 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-11-03 | $-0.62 | $53,436,750 | 3 / 4 |
| 2026-11-04 | $-0.62 | $53,436,750 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.